Good evening. My name is Savannah. I will be your conference operator for today. At this time, I would like to welcome everyone to the Amwell Q4 2022 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star one on your telephone keypad. If you would like to withdraw your question, please press star one again. We ask that you please limit yourself to one question. Thank you. I would now like to hand the call over to Sue Dooley, Head of Investor Relations with Amwell. You may begin. Hello, everyone. Welcome to Amwell's conference call to discuss our fourth fiscal quarter and year-end of 2022. This is Sue Dooley of Amwell Investor Relations. Joining me today are Amwell's Chairman and CEO, Dr. Ido Schoenberg, and Bob Shepardson, our CFO. Earlier today, we distributed a press release detailing our announcement. This release is posted on our website at investors.amwell.com and is also available from normal news sources. This conference call is being webcast live on the IR page of our website, where a replay will be archived. Before we begin our prepared remarks, I'd like to take this opportunity to remind you that during the course of this call, we will make forward-looking statements regarding projected operating results and anticipated market opportunities. This forward-looking information is subject to the risks and uncertainties described in our filings with the SEC. Actual results or events may differ materially. Except as required by law, we undertake no obligation to update or revise these forward-looking statements. On this call, we'll refer to both GAAP and non-GAAP financial measures. A reconciliation of our GAAP to non-GAAP financial measures is provided in our posted earnings release. With that, I would like to turn the call over to Ido. Thank you, Sue. Hello everyone. I'm pleased to report that in Q4, we successfully capped off an important and strategic year for Amwell. On many levels, it was an incredible year. We rallied as a company and executed well, making meaningful progress in the transition to Converge, our software platform that we believe will enable and empower the future of hybrid care, and which has already been embraced and implemented by some of the most demanding and innovative healthcare organizations. I would like to begin by reviewing a few highlights of the quarter. I'll take a moment to discuss the market for our solution and describe key priorities for 2023. After that, Bob will review some key metrics, our financial results in our 2023 guidance. Then, we'll be pleased to take your questions. To begin, here are some highlights. In Q4, we had another great quarter for client migrations, and Converge is scaling well. Specifically, visits on Converge continued to rise and grew from 16% of total visits for the quarter in Q3 to 28% of total visits in Q4. In fact, all of our key operating metrics are trending favorably, and we'll let Bob review that in a moment. Our solution is resonating across all segments of the market. We continue to strengthen our relationships with strategic clients. In one standout example of this from Q4, we formally extended our long-term strategic partnership with Elevance Health. We are proud to be an important part of their digital platform for health, which aims to attract, engage, and retain more clients while also achieving operational goals. We believe this validates the benefits of Amwell as the strategic partner that can empower and enable the future of care. We look forward to the future of this important relationship to help advance innovation from our visionary strategic partner. While endorsement for clients like Elevance in the high end of the market lift the visibility of Converge, our value proposition extends to clients of all sizes. For example, Northern Light Health, located in Maine, is leveraging Converge to drive some of their system-wide goals around access to care, provider experience, and internal efficiencies by consolidating technologies and streamlining workflows. Northern Light is a brand-new client which has rapidly deployed the Converge integrated scheduled visit experience across many practice areas with more to come. Our Physician Champion reports an improved clinical delivery experience with quality and efficiency gains compared to previous telehealth alternatives. We continue to deliver powerful new solutions in partnership with our clients. For example, with Northwell, we extended their existing roster of robust automated care programs to include an AI-driven pregnancy program aimed at reducing mortality. The chatbot, called Northwell Pregnancy Chats, identifies potential urgent concerns, links to care teams for evaluation and analysis, and accelerates time to care for women during and after pregnancy. Northwell delivers 1% of babies in the United States, and so far, the chatbot has been used by over 1,600 patients with satisfaction rate of over 95%. In one powerful example of the benefits of this solution, Northwell helped escalate life-saving care for preeclampsia for a pregnant woman who reported high blood pressure in the chat. This is a great example of our enabling partner model. We collaborate around meaningful products that provide value, deliver outcomes, and empower our clients to set new standard for care. We are pleased with the consistent positive feedback on Converge that is flowing in from our clients. We are executing well, and we have put many of the platform transition-related challenges behind us while building on our track record as the enabling partner for hybrid care. Turning the page to 2023, it is increasingly clear to me that we made the right decision to re-platform our solution. Now, I'd like to speak to the broader environment for a moment and how I see our own role in it. We just completed our Annual Sales Meeting, which was filled with the energy of a new year, the promise of our Converge platform, and the many strong client and partner endorsements of our approach. A lot has changed in the past few years. Our teams are motivated by the certainty that digital-first care is rapidly becoming the main highway for a variety of care modalities offered by all types of providers and services, and our role in this evolution is a significant one. Across our industry, we are facing uncertain times. As we see it in Amwell, economic uncertainty creates both headwinds and tailwinds for us. We know hospital budgets are constrained, the challenges facing providers and payers drive an urgent need to leverage technology to achieve their operational goals. In our sales approach, we strive in every conversation to convey to prospects and clients that our solutions are the must-have engine to resolve their pain points today and deliver on their strategic aspirations for the long run. We understand that ROI and outcomes that materialize quickly are a must in today's environment. At Amwell, demonstrating ROI is in our DNA. This approach resonates with health systems which are prioritizing digital care to achieve important goals around staff burnout, retention, new sources of revenue, and streamlining workflows. We support and embrace patients with our automated programs, engaging them to improve outcomes. We enable models of care that allow our clients to differentiate their own approach to care. Every day, I speak with healthcare industry leaders who are struggling to unify fragmented technologies and define emerging digital care models. They require a partner to work closely with, a partner to simplify this path, a partner who can apply a clinical approach to the underlying software infrastructure and best practices to advance their goals. At Amwell, our differentiation is clear. We have the clinical experience to understand the challenges our clients face. Our platform is purpose-built and future-ready, founded on years of investing and understanding the needs of our clients. Our approach to the market sets us apart. We are a trusted partner. We enable and empower our clients, and never compete with them to deliver new and exciting ways to provide care while achieving important operational goals. As we deliver on Converge and the market responds, we are solidifying our role as a digital transformation partner, supporting our clients in defining and accelerating their strategies and aspirations that differentiate their own offerings. Regardless of the environment, we have used this highly dynamic period in history to undertake our own transformation, one that we believe has earned us a leading role to deliver on the promise of our mission and our long-term model. I'd like to take a moment to share a couple of key priorities for the coming year. As we begin 2023, we are laser-focused on achieving progress toward our long-term financial model with the following three top priorities. First, a top priority remains migrating the balance of our clients onto Converge. We will strive to ensure the successful migration of our remaining provider clients onto Converge and deployments for payer clients have already begun. Another important initiative for us in 2023 will be to ensure the success of our strategic clients. As we continue with these large and complex deployments, we will provide a shining example for clients and prospects of all sizes who look to us for partnership, enablement, and acceleration of their digital care delivery plans. Finally, our sights are set on pursuing the tremendous opportunity to win new clients across the payer and provider universe while expanding our footprint within our existing client base. Reflecting this, we are arming our teams with powerful new selling tools to enable the sales dialogue, and we are upskilling our teams to master the enterprise-level solution-based selling environment we are in. As we pursue these initiatives, we are further empowered by knowing the hard work of 2022 is behind us, and we have achieved a lot. We have completed the core elements of Converge. We have retained the lion's share of our clients. We have effectively migrated clients and grown our percent of visits on Converge. Our client list includes our industry's most far-reaching and innovative organizations, and experienced industry leaders have joined our company and hit the ground running, partnering effectively with our existing talented teams. We look to 2023 aiming to fulfill the promise of our vision of enabling the transformation in healthcare to true hybrid digital care. With that, I would like to turn the call over to Bob for a review of our financials, some key metrics, and our guidance for the year. Bob? Thank you, Ido. Hello, everyone. I'll start with a review of our operating metrics and financial results for the fourth quarter and the year. Then I'll discuss our outlook and guidance for 2023. I'm pleased to report that all of our key operating metrics are trending in a healthy direction. Active providers is an important metric of the sustained value our clients see in our platform. We ended the fourth quarter with over 107,000 active providers, representing growth of over 11% compared to a year ago. As a subset, active providers employed by our clients grew 12% versus last year. We anticipate that our number of active providers will continue to rise as we migrate and implement existing and new clients onto our Converge platform. Another important metric is our average annual contract value or ACV, which is a good indicator of the value we are delivering to our clients and the success of our land and expand strategy. Health plan ACV increased over 19% to $862,000 in 2022 compared to 2021. ACV for health systems saw a 13% increase to $401,000. This is in line with our expectations during this time of the Converge transition as clients focused on migrating to Converge. We expect ACV to continue to expand as we look to grow our footprint within existing clients and add new clients over time. Total visits were approximately 1.7 million in the fourth quarter, an increase of 10% compared to last year. Urgent care visits drove most of this increase in what was the first real flu season since the onset of the pandemic. This surge in on-demand urgent care visits resulted in scheduled visits being 63% of the total, down from a prior range of 70%-75% over the last couple of years, but still up significantly from approximately 30% pre-COVID. For the year, scheduled visits comprised 70% of total visits. We continue to make steady progress migrating our clients to the new platform, and we are proceeding according to plan. In Q4, successful migrations drove visits on Converge for the quarter to 28% of total, and that number has continued to increase during Q1. Now on to our financial results. In a transition year with many moving elements, we are pleased to have been able to achieve our revenue guide and exceed our adjusted EBITDA guide for 2022. Total revenue was $79.2 million for the quarter, which represents growth of 9% over Q4 of last year. Total revenue for the year grew 10% compared to last year to $277.2 million. Subscription revenue was $30.7 million in Q4, relatively flat compared to the year-ago quarter. For the year, subscription revenue grew 12% to $120.9 million. During the year, subscription revenue growth was positively impacted by the inclusion of a full year of revenue from our 2021 acquisitions of SilverCloud and Conversa. Challenged by the temporary impact on bookings we had expected while we focused on completing the Converge build-out, successfully migrating our existing client base, plus strategic client deployments. The diversity of our revenue stream proved to be a real asset in 2022 as AMG and client-related implementation services delivered strong growth for the year, supporting our overall growth rate during this time. Moving to visits. In Q4, AMG visit revenue was 12% higher than last year at $35.1 million. Visit revenue was strong this quarter. In fact, was just shy of Amwell Medical Group's all-time high of $36 million in the second quarter of 2020 at the peak of the pandemic, demonstrating the enduring value of this service to our clients. For the year, visit revenue grew 7% to $124.3 million. On to some detail on visits. AMG visits grew 23% for the quarter and 11% for the year, with average revenue per visit at $71 and $76, respectively. As I mentioned, the early onset of an unusually heavy flu season drove urgent care volumes higher and hence revenue per visit lower for the quarter. As we have said previously, while our AMG business is an important differentiator in the market and critical to many of our clients, our primary focus going forward is to drive high margin, recurring revenue associated with sales of the Converge platform, plus a growing number of modules, automated care programs, and services like AMG. Our services and Carepoint revenue grew 18% to $13.5 million in the quarter and 14% for the year. This strength was driven substantially by professional services revenue we earned as we implemented strategic clients onto Converge. As we have discussed on prior calls, revenues of this type highlight the strategic long-term nature of our client relationships and the ROI they see in deploying our platform. Turning to profitability, fourth quarter gross profit margin increased 250 basis points versus last year to 42.4%. For the year, gross profit margin increased 80 basis points to 42.1%. Gross margins may continue to fluctuate a bit from quarter to quarter, depending on revenue mix. Contributing to the increase for the quarter were a higher proportion of urgent care visits at AMG and a higher margin mix of services and Carepoint revenue. Over the long run, it's our goal to drive a steady revenue mix shift toward high margin, recurring software revenue in pursuit of our long-term model. Turning to operating expenses. During the fourth quarter, our progress in developing Converge crossed a meaningful threshold in our overall project plan. As required by GAAP, we capitalized $10.2 million of development-related efforts in the quarter. Adjusting for these capitalized software development costs, R&D expense increased by $1.6 million in the quarter to $37.8 million. As we have discussed, we believe that 4 Q 2022 represented our peak R&D spend. Given our progress in delivering Converge, we expect that R&D spend will decline sequentially on an absolute basis over the course of 2023. Fourth quarter sales and marketing expense increased 9% compared to a year ago. This was driven by higher sales and marketing activity across the board as we prepared for our January commercial kickoff meeting and ramped our overall sales efforts reflecting the completion of Converge. We made some changes in our sales teams to align our resources around solution selling, which are aimed at driving pipeline development, deal velocity, and deal size. G&A increased 9% sequentially, driven primarily by the recognition of deferred non-cash compensation associated with the terms of our SilverCloud acquisition. Adjusted EBITDA for the quarter was - $43.4 million, bringing the metric for the year to - $175.3 million. As we discussed on our third quarter call, Q4 completed a full year of careful expense management around headcount, and we achieved synergies from the early integration of our recent acquisitions. As a result, we achieved better than anticipated adjusted EBITDA, both relative to our preliminary guide for the year as well as versus our updated guidance last quarter. Transitioning to the balance sheet, we ended the quarter with $538.5 million of cash and marketable securities. We are fortunate to have a substantial cash position as it provides the resources to fund this temporary period of investing and the flexibility to pursue strategic opportunities that are aligned with our goals. Turning now to our 2023 outlook. 2022 ended with puts and takes for our business, which we carefully assessed in arriving at our guidance range. First, we experienced both continued impact from COVID and an early and severe flu season, which may not recur this year. As a result, we took a conservative approach and are assuming normalized AMG visit activity of 1.45 million-1.65 million visits. We also looked carefully at the spending environment, taking into account conversations with our clients. As Ido mentioned earlier, a challenging macro environment presents us with headwinds and tailwinds. On the one hand, the heart of our value proposition and our partnering approach directly addresses the budgetary and operational challenges our clients and prospects are facing today. This is driving demand. On the other hand, these challenges may also impact expansion and deployment cycles for our solution that are difficult to predict at this time. Finally, we anticipate steadiness in our services and Carepoint's revenue, which we believe will remain at approximately 10% of total revenue. Considering these factors, we expect revenue to be in the range of $275 million-$285 million for the year. Given sales cycle timing, we anticipate the majority of the bookings we generate this year will come in the second half of the year. A portion of the bookings momentum we aim to generate this year will translate to revenue growth in 2024. Next, some color on subscription software revenue growth, which is a primary goal for us. We emerge from this time of transition and continue migration, we are turning our attention to re-accelerating client bookings via expanded use of new modules on Converge. With Converge ready and reference clients building, we anticipate a return to strong software bookings momentum. We believe software revenue will grow faster than our overall business in 2023. On to our guidance for our progress toward profitability. For the full year 2023, we expect our adjusted EBITDA to be in the range of - $150 million to $160 million. Much of the expected improvement in adjusted EBITDA will come from the anticipated reduction in R&D spending layering in over the course of the year as we have planned. Wrapping up our guidance, we are encouraged by our progress to date. All of our key metrics are trending favorably. We have put much of the risk of our transition behind us. Our teams are executing in product and client migrations. We have earned the validation that our anchor clients ascribe to our approach to the market. The clients we have implemented onto Converge report a very high level of patient and provider satisfaction and technical success. They give us valuable referenceability with our prospects. Our ROI case studies are fueling robust conversations with our substantial pipeline of upsells and new logos. Before I conclude my remarks, I would like to comment on our long-term model as we outlined a year ago. As we enter the next chapter of our transition, we remain confident in the components of our long-term model, which describes our path to cash flow breakeven and remains our goal. We believe our differentiated approach to enabling digital care delivery positions us well to deliver sustained revenue growth and expanding profitability over the long term. Thank you for listening. With that, I'd like to turn the call back to Ido for some closing remarks. Ido? Thank you, Bob. Before we conclude our prepared remarks and take your questions, I want to take a moment to thank our teams. They dedicate their talents to developing and deploying our solution, extending our market reach, delivering thought leadership around our mission, and finally, contributing to our unique company culture. In closing, we are driven every day at Amwell to continue along this path to achieving our goals and pursuing our mission. Our solution is in high demand because it solves important problems for innovative healthcare organizations seeking to evolve to hybrid digital care. We begin 2023 on strong footing. While there remain broader environmental uncertainties in our world today, it's early days for digital-first healthcare. Our role is unique and differentiated, and the opportunity before us has never been brighter. With that, we're ready to conclude our formal remarks. Thank you for listening today. Operator, we are ready to open the line for questions. Thank you. Thank you. At this time, I would like to remind everyone in order to ask a question, please press star and then the number one on your telephone keypad. We do ask that you please limit to one question, and we will pause for a moment to compile the Q&A roster. Our first question will come from Craig Hettenbach with Morgan Stanley. Please go ahead. Craig, your line is open. We will move on to our next question from Charles Rhyee with Cowen. Please go ahead. Hi, this is Lucas on for Charles. Wanted to dive into the 2023 revenue guide implies growth that's a bit lower than we had expected. Obviously, it's well documented the difficulty that health systems are dealing with right now. You know, kind of wanted to dive into conversations you guys are having with your customers. Is the, you know, is there something slowing with the migration to Converge? Are customers delaying things on their end? Is it more of customers pulling back, or are they just putting projects on hold for second half? If you could give more color around that, that'd be great. Thank you, Lucas. I appreciate the opportunity to talk about that. As I mentioned in our prepared remarks, we are actually executing very much exactly or even better than our plan. 2022 was a year of transformation where we re-platform our major offering. This is a high-risk time for any company, and the risks include potential churn, the delivery of the new platform, the ability to migrate clients to the new platform, to name a few. As I mentioned before, we did that and some. We finished the year with a solution that is ready for prime time, and not only that, we were able to convert 28% of our traction into the new platform that is dramatically more efficient, more sticky, and more expandable, with very significant wallet share, same-store growth opportunity going forward. Very importantly, maybe to add, we did that while retaining the line share of our customers and practically 100% of our strategic customers, which is far from obvious. In addition to that, we're able to have some very sophisticated large clients like CVS, Elevance, and others that we did not disclose yet, make a long-term decision on the new platform. Looking back, we couldn't have asked for a better outcome for the year. At the beginning of the year, we were able to part ways with an army of contractors that helped us create the core components of the platform that is already now being deployed, adding to the efficiency. Because of these dynamics, we always knew that 2023 will be a muted year, only because you are unable to sell a platform that is not yet finished and all the dynamics that I just shared. Adding to that, there were two trends, headwinds, that I'd like to point out that weren't as apparent last year and maybe also related to your own expectations. One is the macro. The macro obviously is an unknown as it relates to 2023, but it has the potential to impact sales cycles, deployment cycles, velocity of expansion, and things of that nature. While our solution is a must-have, and our clients keep telling us this potentially could become a barrier for further growth this year. In addition to that, we noticed interesting dynamics as it relates to the flu and the pandemic. In Q4 this year, it actually panned out to be very positive in the sense that it was a very strong flu season and associated revenue with it, but can just as easily play the other way this year. We felt it was responsible to take those two headwinds into account as we present our guidance, protecting our downside. Also, because of those headwinds, we felt that it's not prudent to include a long list of tailwind that we see. We know our platform is scaling well. We know it's in very much very high demand. It is validated by so many sophisticated organizations, and it's very timely in way of market that is very well positioned to grow very aggressively over the next few years. That's maybe a long answer to your short question, but that's really how we ended up with the guidance that we just shared. Okay. Yeah, that's helpful. In terms of your profitability guide, it seems like OpEx is going to be in a similar range to our expectations and the street's expectations. Wanted to hear if we should still think about adjusted EBITDA breakeven by year 2025, and if that expectation has changed at all? Lucas, I'll take that. It's Bob. Just taking the opportunity to rewind the clock a little bit to about a year ago when we put out that guidance. There were three kind of core assumptions underlying that path to profitability framework, and all of them at the time had different degrees of risk. The first was a continued strong demand for digital care enablement. As we sit here today, you know, we believe that the market opportunity is only better than we thought a year ago. Large strategics are voting with their feet on that. The second one, second key assumption underlying that model was that we would deliver Converge and migrate customers, begin to migrate customers over 2022 to get us on a path to where we could sunset the legacy platform and realize the efficiencies associated with that. The proof in the pudding there is, you know, from a standing start, we went to 28% of our visits this quarter or this past quarter on the new platform, and that's continued to trend higher. I think that's a check there too. Then on the last key assumption there was that once we delivered Converge, the core components of Converge, that R&D would normalize. That's happening. You know, you'll see that in the first quarter, start to present, and it'll continue to get better as we were able, as Ido said, to sunset the contractors that had really been the backbone of a lot of that incremental spend on Converge. All of that kind of provides the foundation for bookings and revenue acceleration and our margin improvements. As we sit here today, visibility on all of that is much better than it was a year ago. But there are things we don't control, like the macro that Ido just went through, and that can influence the pace positively or negatively to when we get to that break-even path. If there is a delay, we're certainly well equipped to handle that. We've got the balance sheet to weather that. Now that we've got a commercial platform in the market, a lot of our spend you could consider discretionary. We have much, you know, a lot more levers to play with than we have over the last couple of years when so much of our spend has been driven by delivering Converge. In summary, we can get there, but if we're delayed, we don't see any change in the fundamentals. Our next question will come from Ryan MacDonald with Needham & Company. Please go ahead. Hey, thanks. This is Matt Shea on for Ryan MacDonald. Thanks for taking the question. Wanted to follow up on the 2023 guidance and start with the revenue. We were a little bit surprised to see platform revenue decline sequentially in the fourth quarter. Based on some of the building blocks for 2023, it looks like it's gonna come in lower than expectations in 2023 as well. Just curious, was there churn in the quarter that caused the sequential declines or the outlook for 2023, or is this solely just a bookings timing consideration? Maybe you could remind us what the bookings conversion cycle looks like for Converge bookings to revenue. Thanks. I'll take that too. You know, I think what you ended with was really the most important aspect of the answer to the question. Again, this is, you know, 2022 very much a transition year, and with it brings challenges beyond the macro. We did see customer churn at the low end, especially at the low end, where the switching costs are a lot less, in the market. And beyond that, limited amount of churn that we saw at the low end, you know, customer expansions are by their nature with the replatforming delayed, and new prospects want to evaluate the new platform before they sign up for multi-year contracts. That dynamic is very much evident in, you know, really, we've been living with that for a lot of the last almost couple of years at this point. We're now at a point where we have a commercial platform in the market, and that plus a lot of tools, you know, in the toolkit for our sales force, we think is gonna allow us to really start to inflect on the booking side, which is gonna drive, obviously, revenue growth. To give you a sense for the time from booking to revenue, you know, it really depends on how large the customer is and how complicated the implementation. A reasonable expectation there, taking into account scheduling on the customer side, our side, and then the work is probably five to six months, you know, on average. You can imagine with bookings building over the course of the year, and then, you know, revenue starting to present from that, you know, more in the back half of the year, and then driving really growth into 2024, the that's the dynamic going on with, what's perceived to be, you know, I think muted, guidance for the year on the top line. Got it. That is super helpful. Keeping in mind, it sounds like same-store growth is gonna be a big focus, and you guys have talked about some of the changes to the sales force to align with that. Previously, you've talked about maybe a cadence of 16-20 weeks where a customer comes onto Converge, realizes the value, and then you guys can upsell additional modules. Have you guys seen some clients complete this journey? And if so, what does it kinda look like? Maybe what modules are the highest demand for them to upsell to, and how do you see that trending going forward? Thanks. Sure, Matt. It's hard to compare Converge to our legacy platforms. Converge is so much bigger, can do so much more, and has so many modules that really cater to a very wide spectrum of needs. Of course, not all our clients need everything at once. It's very common that they focus on the pain points that are important to them today, but they take great comfort in knowing that they can really expand in a very material way to many directions. Another trend that is very apparent is our success with very large customers. Those customers usually buy from the get-go many use cases, although the deployment is staged. They throttle up. It's not binary. They don't do everything at once just because of operational reasons, but they do have an healthy appetite, and the ACV in those clients is significantly higher than what we've seen before. When we think about it, we really want to make sure that we maintain our very large footprint in the U.S. healthcare that we had before, and that certainly seems to be the case, and the odds look better and better every day and really establish a trusting, a lifelong or at least very, very long relationship with those clients as we serve their needs as a partner, as the needs really evolve. Saying it another way, if you think about digital care delivery, it's really hard to overstate the proportion and the importance of that transformation, in the proportion of business of our customers. The net of it really depends on different clients. We see examples all over the spectrum. We believe it's a timing issue. Some of the larger organizations, especially payers, they have the capability to deploy more and the need to differentiate faster and accomplish more. Others are a little bit more careful in that environment, but they all trend in the direction of good appetite. I'm pleased to also share that even on our smallest clients with simpler use cases, some of which we lost through transition, we see a trend of coming back as they discover the need to buy more modules that are more sophisticated. To give you more color on that maybe to be more specific, when we look at payers, the enablement of digital first in navigation we feel is very much in demand today. Obviously it allows them to offer a phenomenal member experience in also very efficient way to route those members financially and clinically to the most appropriate physical, virtual or automated intervention. The benefit of that is that all those modalities work in harmony around a single patient experience. When we think about health systems, as Bob mentioned earlier, they really care very much about staff retention these days, patient experience, improved efficiency and opportunity to diversify revenues by going beyond their patient area and begin to trade information and services with other segments, very often payers that they can serve. That's another very important trend. The platform is very wide. There are many, many examples. The power of the platform is the fact that it's a single platform that serves the entire market. Really our clients are coming with new and innovative ways to leverage that. That trend is likely to greatly accelerate and expand going forward. To net it all, we believe that we are in the very early innings, in the very early days of realizing the potential of the same-store growth, with our existing customers. In the interest of allowing everyone a question, we would like to remind everyone to please keep your question to one. Our next question will come from Craig Hettenbach with Morgan Stanley. Please go ahead. Hi. Hi, can you hear me okay? Yes. Hi, Craig. Yes. Oh, great. Apologize for the audio issues before. Just wanted to follow up on the comments around ACV and the growth that you saw this year. Particularly as you kind of play out this year and going forward, just how you're thinking about the momentum behind ACV and any particular, you know, modules that you would call out, whether it's an update on the behavioral health side or things that you feel the most, you know, where you're seeing the best customer response? Well, just on the Craig, I'll just take a little bit on ACV and then Ido can address maybe some of the specifics around modules and behavioral. We did see, especially on the health plan side, very nice growth in ACV, driven, you know, actually both by existing customers taking more, so same store sales and new logos. That's very much in line with our plan and what we expect going forward. On the health plan side, I'm sorry, on the health system side, a little bit more complicated of a story. Still, nice tick up there, but there are a number of moving pieces on the health system side. We had some benefit from consolidating, you know, a full year of revenue from SilverCloud and Conversa, you know, for their customers on the health system side. We also, you know, unfortunately did see some churn at the low end. As we've said a number of times here, and Ido did mention that we're starting to see some come back, but that did impact positively because we lost some small inputs to the average the ACV there. So, you know, puts and takes there and obviously, you know, some movement around upsells as well was helpful. But, it netted out to reasonably attractive growth on the ACV side for systems. And again, you know, we expect with bookings and revenue growth on the health system side, the bookings more this year driving revenue growth in the second half and into next year that also tick up. We expect growth on both. It's a key driver for revenue growth, you know, for us, you know, along with new logo signings. You know, I think that's really, I think, an explanatory around the movements this year. Ido, if you wanna provide some color around where that growth is, as Craig is asking, we expect that to come from a module perspective. Absolutely. Essentially, there are many areas of unmet need for the U.S. patient or really patients around the globe. Our unique approach is not to try to fix it with the service ourselves, but rather enable the connectivity to the trusted sources of care and empower them to focus their time significantly more efficiently. You raised a really important therapeutic area, which is behavioral health. Unfortunately, we see a full-fledged crisis now in the United States that drives different types of demand, including rise in out-of-pocket DTC payments for different modalities of care, with mixed results. We have a clear vision on how this should play out, but essentially, the method is similar to any other therapeutic area that we enable, which is to leverage the trusted providers that we know that are integrated in our normal main pathway of care and just allow them to be dramatically more effective. A good example, a case in point is SilverCloud, that we acquired last year. SilverCloud, as you may remember, was able in the U.K. to dramatically increase the ratio between the number of therapists and the number of patients that they can care for more than fourfold, more than four times. As a result, a dramatic decline in the cost per intervention. We did that not by hiring an army of psychiatrists and psychologists, but rather empowering the existing therapists to be much more effective with their time by automating a lot of tasks. That's the Amwell way in many ways. We see very strong demand for behavioral health enablement and efficiency. We definitely believe, as you rightfully guessed, that this is going to be a very high-demand module as Converge is being deployed this year. There are many other examples beyond the time that we have right now. Our next question will come from Jack Wallace with Guggenheim Securities. Please go ahead. Hey, thank you for taking my questions. Just wanna ask the ACV question, as it relates to the guide just a little bit differently. It sounds like you don't expect, you know, many new logos this year. It's an expansion within the client base here. Within that expansion, you know, my sense is that this is mostly upsells, versus, say, intensity of use or your clients, using the core platform across, you know, whether it's, you know, more facilities or more settings. Is that the case? Not at all. I'm not sure how you got this impression. We maybe weren't clear enough. We see extraordinary demand for Converge by both existing clients and new ones. The decision to migrate is not an obvious decision. It takes time and integration, training, and things of that nature. The fact that we in these uncertain times, we see such strong adoption for the new platform is very encouraging. CVS definitely was not alone as the new organization that understood the value of the Amwell, the new Amwell platform, and we definitely plan to see others. The guidance is focused on revenues, not on bookings. We definitely see that as a year of significant acceleration as it relates to booking, the recognition of which is dependent on various factors, including the macro and the pace of our customers, that we need to be careful in in predicting. I would love for all of you to be with us to hear verbatim what the Converge clients are saying these days and the level of enthusiasm and encouragement. That's true not only for existing customers, that's definitely true also for new ones. Our next question will come from the line of Hanna Lee with Bank of America. Please go ahead. Hi, this is Hanna Lee on for Allen Lutz. Thanks for taking my question. Just was wondering if you can provide additional color on the composition of revenue growth for 2023. Is it primarily coming from subscriptions or visits? We, Hanna, thanks. We provided guidance for visit for the number of visits that we expect for AMG, for Amwell Medical Group. You'll see that that is fairly conservative relative to what we posted this past year, primarily because we, you know, don't wanna aggressively assume that we again see COVID spikes as well as early and severe flu in 2023. I think we've been conservative there. On the, you know, I guess we would expect, I would give a little bit of guidance that we would expect that our software line item, subscription revenue, would grow faster than the overall revenue growth that is assumed for the entire organization. I think that gives you a sense as to, I guess, what's going to drive and what the components of it look like. Our next question will come from Jailendra Singh with Truist Securities. Please go ahead. Hi, this is Jay on for Jailendra. Thanks for taking my question. I kinda wanna touch upon CVS there. It is clearly a huge implementation, so I'm wondering if you can talk about what kind of contribution is assumed in your guidance. Additionally, anything to share in terms of how the rollout has been so far, and how do you think about the opportunities this might open up with CVS on additional areas. Thank you. Sure. As many of the participants know, we are very careful not to talk specifically about our customers. We are an enablement platform that participates in realizing important business goals for our customers, and they usually like to share it when they're ready. CVS already shared that we are the backdrop of their very large cross-company initiatives for digital care enablement, and we can't be more grateful. Our relationship with this partner is very strong, and we're very optimistic about its future and its potential for expansion. I would say more generally, and not necessarily about them, but really true for many customers, especially the bigger ones, usually our business model is such that there is a startup recurring fee for the baseline, and then as more traction, more use, larger addressable audiences participate, and the client total ups, we are increasing our value and revenue capture from there. Really there is no exception to this business model. The potential for the likes of CVS to grow within their own very large footprint already and even impact the entire ecosystem in various ways could not be overstated. However, we cannot automatically assume anything in our guidance. Per design is really assuming things that we have extremely high visibility to. There is nothing unnatural in our guidance, and the visibility is only for things that we think are extremely likely to happen. Although there is a enormous amount of upside that we believe in, we're just not sure exactly how it's going to play out in real timing and rhetoric. Our next question will come from Eric Percher with Nephron Research. Please go ahead. Hi, this is Dolph on for Eric. Thank you for taking our question. A lot of our questions have been asked already, but with respect to the services, revenue expected to go to 10% of revenue this year, I just wanna gain an understanding of how temporal in nature that is, and how much would be expected to continue into next year. Thank you. Dolph, I just wanna make sure I'm understanding the question. Are you asking a quarterly question or is it, how much, you know, are you asking how the quarters lay out? I'm not sure. I'm not sure at all. I'm sorry. I think I caught that services revenue are expected to be 10% of total revenue this year. Yep. Did I hear that? You did. Is that if we think about what's driving that revenue, is that something that we would expect to continue to grow in future years, or is there any kind of lumpiness to this year versus future years that we should be kind of considering? Well, it was more I guess in 2022 it was more than 10%. There was some lumpiness in that. We, you know, and the lumpiness really is mostly attributable to you know, large, complex custom integrations that we take on. And so, pegging when those are gonna happen or how often they're gonna happen is difficult. That's just a component. It kinda drives, you know, up or down the percentage of revenue. The other components of it obviously are Carepoints, you know, which have kind of an attach rate to how we're doing on, you know, sales to or bookings to health systems. There's also, you know, some marketing campaigns that we help out on for a number of our clients. Those have been a very regular component of our revenue through the years as well. You know, the marketing revenues and the Carepoint revenues, you know, I expect those to continue much as they have in the past. The, you know, the implementation-type revenues, lumpy, tougher to predict, very high value as they're really indicative of, you know, a good forward indicator of revenue to come. I can't really give you much beyond that. Our final question will come from the line of David Larsen with BTIG. Please go ahead. Hi. It's my understanding that Converge is a very comprehensive platform. It is a full digital-first solution. That's one of the reasons why CVS selected you to be one of their key vendors going forward. I agree with that strategy. Can you maybe talk about how many sort of different kinds of modules beyond sort of pure telehealth are now part of Converge? Is there like diabetes, cholesterol, mental health? Are there maybe like 10 or 20 additional sort of digital health modules that have plugged into Converge? Is there a higher price point depending on how many different modules your clients select? Just any color around sort of the incremental revenue contribution for those would be very helpful. Thank you. Hi, David. You're absolutely correct. There are really two things here to bear in mind. One is Converge is indeed a platform, and it's a very open platform, and it's designed to really bring together the patients, providers, other participants around the entire spectrum and types of care that are physical, virtual, and automated, but also across the entire care continuum in an integrated way. It's quite a task. Obviously, we don't expect ourselves to offer all those services, nor do we think that's the right way to go at all. Rather, we are enabling the connectivity, the integration, the orchestration more than anything else. In that way, Amazon is much closer to Amwell than Epic, for example, in the way of in the way, in the way that we operate. Converge is very easily open to third party, whether it's medical devices or different type of programs and so on. We don't count them anymore. There are in the hundreds of more of those packages, if you will. Many of them are made not by Amwell. They're made by the like of Sword and TytoCare and the Cleveland Clinic and really many other entities that want to participate in the integrated experience. The integrated experience is extremely important for our buyers. CIOs today struggle with enormous fragmentation and everybody else is suffering, including patients and providers, by needing to log to multiple apps and services. These are often not connected, a source of errors and cost in customer acquisition and in other ways. As we grow, we definitely plan to include some anchor applications from services like automated behavioral health, which we think are very, very important, or second opinion through our JV with the Cleveland Clinic, is great examples and use cases for the ecosystem. We fully expect a really limitless amount of programs and services to be offered by others. We definitely plan to monetize the value of integration, both by the impact it has on risk bearers on the one hand, and that's the important part, but also by allowing access to different vendors and innovators that really dramatically reduce their entry point into the covered services and the audiences that our clients represent. I hope that a little bit clear. That will conclude today's question and answer session. Ido Schoenberg, I turn the call back over to you. Thank you very much, operator. Thank you very much, everyone. We really appreciate your support of Amwell and our journey through Converge, and we look forward to talking with you again soon. Have a nice evening. This concludes today's conference.